Introduction

Neuroblastoma
is one of the commonest malignant solid tumors observed in childhood.
Although significant progress in the control of other malignancies, such as Wilms' tumor, osteosarcoma and rhabdomyosarcoma, is being made with multimodal treatment, an effective therapy for advanced neuroblastoma has not been found (Sutow, 1981 Table 1 . There were 9 boys and 7 girls, ranging in age from 8 months to 7 years and 8 months (median age was 1 year and 11 months).
Clinicopathological staging was determined after a laparotomy which included tumor resections or biopsy. According to Evans' criteria (Evans et al. 1971 The 16 patients with advanced neuroblastoma were treated with one of two different chemotherapy protocols in a nonrandomized fashion. The outline of the two protocols are shown in Table 2 . The patients constituted two groups. Group A, consisting of 6 cases was treated with the James' therapy (James et al. 1965 ) plus ADR, and Group B, consisting of ten cases, was treated with the "high-dose CYD" regimen. Group A patients received VCR at a dosage of 1.5 mg/m2 on five days (days 8, 22, 36, 50 and 64) , CYD at 300 mg/m2 on six days (1, 8, 15, 29, 43 and 57) and ADR at 1 mg/kg on days 73 and 74 changing to 0.5 mg/kg on days 87 and 88. Group B patients were treated with VCR at a dosage of 1.5 mg/m2 on days 1 and 8, ADR, 20 mg/m2 on day 4, and CYD, 10-30 mg/kg on days 1, 2 and 3. This alternation of VCR, ADR and CYD was continued for at least two years, in a three week cycle.
The total dose of ADR for Group B patients did not exceed 450 mg/m2. Ra- (Sutow, 1969) for the management for rhabdomyosarcoma.
The original VAC regimen has been subsequently modified to give CYD at higher dosages rather than on a daily low dosage schedule (Finklestein et al. 1969; Haddy et al. 1967) . Now the original and modified VAC therapies receive much support because the clinical effectiveness of the combination is significantly better than the effectiveness of any one of the drugs used alone.
With respect to the multiagent chemotherapy for neuroblastoma, a combination of VCR and CYD was suggested by James and co-workers in 1965. This produces more extensive and more frequent regressions of the tumor than either agent alone (James et al. 1965 ). Since then, there have been many reports on adjuvant chemotherapy for advanced neuroblastoma.
In 1972, Helson and coworkers reported that in patients with disseminated neuroblastoma, the administration of three drugs in sequence (VCR, CYD and AMD) re-suited in a median survival of 18 months, but unfortunately did not affect the cure rate (Helson et al. 1972 ). In the following year, they described the use of four drugs, VCR, CYD, AMD and ADR. This produced minimal additional benefit when compared to the three drug regimen. They concluded that to improve the cure rate in children with disseminated neuroblastoma, more effective agents or alternative drug regimens must be developed (Nelson and Denoix, 1973) . Gasparini and others reported a median survival time of 17.5 months in 11 responders among 19 patients with Stage N neuroblastoma and a median survival time of 5 months in the 8 nonresponders in this group. The overall median survival time was 13.2 months (Gasparini et al. 1974) . In 1979, a report on multiagent chemotherapy for children with metastatic neuroblastoma by the Childrens Cancer Study Group (CCSG) between 1971 and 1975, was done by Finklestein and others.
One hundred and four patients with metastatic neuroblastoma were evaluated for tumor responses.
The three-drug regimen of CYD, ADM, VCR and imidazole carboxamide, and also a similar regimen plus ADR, did not significantly alter the median survival time in these children, although long-term survival was significantly increased compared with previous CCSG studies (Finklestein et al. 1979) . Helson (1979) also reported that some Stage N patients finally succumbed to the disease. The median survival time was six months with a range of 24 months. The 45 patients with disseminated neuroblastoma were treated by multi-drug regimens. At the present time, the overall survival rate of children with advanced neuroblastoma is disappointing, and unchanged from previous results. It is clear that aggressive chemotherapy should be given to children with neuroblastoma. There is no data which indicates that a consistent and significant improvement in the survival rate occurs with chemotherapy.
Temporary responses have occurred in advanced neuroblastoma after administration of a number of drugs. Among these drugs, the most effective agents which have been and are being used in various chemotherapeutic regimens, are CYD, VCR and ADR (Carlsen et al. 1981) . Additionally, ADR and cisplatin (DDP) have been shown to be effective as single agents for neuroblastoma resistant to conventional therapy, and the specific combination of these two drugs has resulted in some complete remissions and some partial remissions (Nitschke et al. 1979 (Nitschke et al. , 1981 . The highdose CYD therapy has received much attention after a report by the Memorial Sloan Kettering Cancer Center Group (Nelson, 1979) . Recently, Uchino's group reported that high dose CYD therapy was effective for the primary tumor of neuroblastoma, but ineffective for the control of bone, lymph nodes, and liver metastasis, in a clinicopathological study of 14 autopsied children with advanced neuroblastoma. By comparison with the results of James' therapy, they concluded that a more effective therapy for controlling metastasis is necessary to improve the results of the treatment of the advanced neuroblastoma (Sasaki et al. 1983 
